摘要
目的分析乙酰半胱氨酸联合布地奈德福莫特罗治疗慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)稳定期患者的效果。方法选取2022年8月—2023年12月东莞市水乡中心医院收治的COPD稳定期患者65例为研究对象,采用随机数字表法分为对照组(n=32)和观察组(n=33),对照组采用布地奈德福莫特罗进行治疗,观察组采用乙酰半胱氨酸联合布地奈德福莫特罗进行治疗,对比2组肺功能指标、症状严重程度、运动耐力和生活质量。结果观察组治疗后第1秒用力呼气容积(forced expiratory volume in one second,FEV_(1))、用力肺活量(forced vital capacity,FVC)、FEV_(1)/FVC肺功能指标分别为(2.67±0.71)L、(2.97±0.81)L、(56.07±5.37)%,高于对照组的(2.07±0.60)L、(2.07±0.44)L、(50.24±4.27)%,差异有统计学意义(P<0.001)。观察组疗后COPD评估测试(COPD assessment test,CAT)评分为(13.82±4.31)分,低于对照组的(18.44±4.84)分,差异有统计学意义(P<0.001)。观察组治疗后6MWT距离为(310.24±20.84)m,长于对照组的(294.81±21.30)m,差异有统计学意义(P<0.05)。观察组治疗后心理功能、躯体功能、社会功能、物质生活4个维度生活质量评分高于对照组,差异有统计学意义(P<0.001)。结论乙酰半胱氨酸联合布地奈德福莫特罗联合治疗方案在COPD稳定期患者的治疗中展现出显著优势。
Objective To analyze the effect of acetylcysteine combined with budesonide formoterol in the treatment of patients with stable chronic obstructive pulmonary disease(COPD).Methods A total of 65 patients with stable COPD admitted to Dongguan Waterfront Zone Central Hospital from August 2022 to December 2023 were selected as the research subjects.They were divided into the control group(n=32)and the observation group(n=33)by random number table method.The control group was treated with budesonide formoterol,and the observation group was treated with acetylcysteine combined with budesonide formoterol.The pulmonary function indicators,symptom severity,exercise endurance and quality of life of the two groups were compared.Results The pulmonary function indicators of forced expiratory volume in one second(FEV_(1)),forced vital capacity(FVC)and FEV_(1)/FVC in the observation group after treatment were(2.67±0.71)L,(2.97±0.81)L and(56.07±5.37)%respectively,which were higher than those of the control group[(2.07±0.60)L,(2.07±0.44)L and(50.24±4.27)%],and the differences were statistically significant(P<0.001).The score of the COPD assessment test(CAT)in the observation group after treatment was(13.82±4.31)points,which was lower than that of the control group[(18.44±4.84)points],and the difference was statistically significant(P<0.001).The 6MWT distance in the observation group after treatment was(310.24±20.84)m,which was longer than that of the control group[(294.81±21.30)m],and the difference was statistically significant(P<0.05).After treatment,the quality of life scores of the observation group in the four dimensions of psychological function,physical function,social function and material life were higher than those of the control group,and the differences were statistically significant(P<0.001).Conclusion The combined treatment regimen of acetylcysteine,budesonide formoterol shows significant advantages in the treatment of patients with stable COPD.
作者
萧锦联
钟伟建
周雪莹
XIAO Jinlian;ZHONG Weijian;ZHOU Xueying(Department of Internal Medicine,Dongguan Waterfront Zone Central Hospital,Dongguan Guangdong 523000,China;Department of Obstetrics,Dongguan Songshanhu Central Hospital,Dongguan Guangdong 523000,China)
出处
《中国卫生标准管理》
2025年第13期138-141,共4页
China Health Standard Management
基金
2022年东莞市社会发展科技项目(20221800906232)。
关键词
慢性阻塞性肺疾病
稳定期
乙酰半胱氨酸
布地奈德福莫特罗
肺功能
效果评估
chronic obstructive pulmonary disease
stable period
acetylcysteine
budesonide formoterol
lung function
effect evaluation
